Objective. This study set out to identify the neuropathic component of pain experienced by burning mouth syndrome (BMS) patients evaluated using painDETECT, a diagnostic tool that could easily be introduced into clinical practice.
Introduction
The International Headache Society defines burning mouth syndrome (BMS) as an intraoral burning sensation for which no medical or dental cause can be found. It is characterized by three diagnostic criteria: 1) pain in the mouth present daily and persisting for most of the day; 2) oral mucosa of normal appearance; and 3) absence of local and systemic diseases [1] [2] [3] .
Different studies have assessed the prevalence of BMS as between 0.2% and 12% of the general population [2] . It can manifest as a dry mouth sensation and alterations to taste whereby bitter or metallic tastes of food stand out. The lack of clear criteria for diagnosis complicates epidemiological studies of BMS, but it would appear to be especially prevalent among postmenopausal women [1] [2] [3] .
Some researchers claim that there are perhaps three subclinical types of BMS [4, 5] : 1) patients affected by peripheral neuropathy with thin fiber dysfunction (representing some 50% of cases); 2) possible major subclinical central trigeminal neuropathy (representing 20-15% of cases); and 3) inhibitory dopaminergic deficiency (20-40% of cases).
Neuropathic pain is characteristic of many BMS cases, but this factor is not widely acknowledged in clinical V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com practice. Its evaluation could be a key factor in establishing protocols for gold standard diagnosis and treatment. In this context, evidence-based recommendations put forward by nonspecialists advocate the use of questionnaires to identify patients with possible neuropathic pain [6] [7] [8] [9] [10] [11] [12] [13] . Establishing the nature of the pain experienced by BMS patients is essential to providing a treatment that effectively relieves and manages orofacial pain [14] [15] [16] . These questionnaires are easy to use and economical, do not require special equipment, and show high sensitivity and specificity. The simple painDETECT questionnaire has been developed to discriminate between nociceptive and neuropathic pain [12, 13] .
The objective of this study was to identify the neuropathic component of pain experienced by BMS patients and describe its characteristics using the painDETECT questionnaire (PD-Q).
Methods

Study Design
This was a cross-sectional prospective controlled clinical study a single center study fulfilled STROBE and Declaration of Helsinki guidelines. The study was performed over a 12-month period and was approved by the Ethics Committee of the University of Murcia.
Participants
Of 78 eligible patients, 12 would not give their consent to take part, so the study included 66 patients, 33 with BMS and 33 patients suffering nociceptive pain. Two nociceptive pain patients left the study before completion as they found it overly time consuming. A total of 33 consecutive patients complaining of a burning sensation and pain in their oral mucosa and 31 consecutive nociceptive pain patients were recruited from the Department of Oral Medicine (Faculty of Medicine and Dentistry, University of Murcia, Spain).
Inclusion criteria for participating in the study were age older than 18 years, willingness to give informed consent to take part, and diagnosis of BMS in accordance with the International Classification of Headaches (continuous symptoms of oral burning or pain on a daily or almost daily basis, during all or part of the day for more than six months) [1] . Exclusion criteria were oral or endocrine lesions; diabetes mellitus; immunological, nutritional, or infectious disorders; history of head and neck malignancy; radiation therapy to the head and neck area; poorly managed and/or chronic thyroid disease, known Sjogren's disease; and incapacity to respond to the questionnaire. Eligible nociceptive pain subjects were patients attending the clinic and diagnosed with oral lichen planus, oral candidiasis, traumatic oral ulcer, or recurrent aphthous stomatitis, identified and recruited consecutively, who presented similar demographic characteristics (age, gender, education, and employment) to the BMS group.
Clinical Assessment
All patients were examined by a trained clinician. Clinical assessment consisted of registering the patient's medical history and assessing pain, its location and intensity. Demographic data (age, gender, habits, marital status, employment situation, educational level), duration and location of symptoms, and clinical antecedents were also registered.
painDETECT Patients completed the questionnaire at the dental clinic. It consists of nine items: Seven descriptive items describe the patient's sensorial experience rated on a scale of 0-5 (never, hardly noticed, slightly, moderately, strongly, and very strongly), one item for pain radiating pattern (0 or 2 points), and one item for pain temporal pattern (À1 to 1 point). For diagnostic purposes, a validated algorithm was used to calculate a total score ranging from 0 to 38. No physical examination was required to assess the intensity of neuropathic pain, characterize symptoms, or determine the presence of nociceptive pain (a score of less than 12), possible neuropathic pain (score of 12-19), or certain neuropathic pain (scores of over 19) (Freynhagen et al. 2006 ) [13] . The questionnaire has been translated into Spanish, and the Spanish version validated (De André s et al. 2012) [12] .
Pain Intensity Visual Analogue Scale
A visual analogue scale (VAS) was used to assess the intensity of pain. This is an effective and easy-to-use, one-dimensional qualitative scale. Patients mark a 10 cm scale ranging from absence of pain (at the 0 cm end) to maximum pain (at the 10 cm end); the distance between 0 and the patient's mark indicates the intensity of the pain suffered.
Hospital Anxiety-Depression
The Hospital Anxiety-Depression (HAD) scale was used to evaluate each patient's psychological profile. This instrument consists of two subscales relating to anxiety and depression. Each subscale contains seven items pertaining to mood disorder. For interpreting HAD scale scores, >10 indicates the probable presence of anxiety or depression, scores of 7 or less indicate no significant anxiety or depression, and scores of 8-10 are of borderline significance [17] .
Statistical Analysis
All analyses were conducted using SPSS software, version 19.0 (Release 19.0; SPSS Inc., Chicago, IL, USA). A descriptive study was made for each variable. Comparisons of the two groups were made applying Student's t test, chi-square test, or Mann-Whitney U test as appropriate. Logistic regression analysis was used to predict the probability of neuropathic pain detected by the PD-Q in BMS. Statistical significance was established as P < 0.05.
Results
A total of 64 patients were analyzed, 33 with BMS and 31 nociceptive pain patients (19 OLP Table 1 shows the demographic and clinical characteristics of the two groups. Mean pain among BMS patients evaluated by VAS was 6.1 6 1.9 and 4.3 6 1.7 among nociceptive pain patients with statistically significant difference (P ¼ 0.001). Among BMS patients, the tongue was the most commonly affected area, followed by the lips and palate. The average evolution time in BMS patients was 3.16 years. When PD-Q descriptors were analyzed (Table 2) comparing the BMS and nociceptive pain patients, statistically significant differences were found for burning sensation (P < 0.010), prickling (P ¼ 0.001), electric shock-like sensation (P ¼ 0.046), thermal sensation (P < 0.001), and numbness (P ¼ 0.002). The PD-Q obtained 21% of BMS patients with scores !19 in favor of certain neuropathic pain.
Logistic regression analysis of patients with pain-DETECT scores !19 (Table 3) found that for the variables assessed the BMS group presented an odds ratio (OR) of 5.23 (95% confidence interval [CI] ¼ 1.35-9.31) and for mean VAS pain an OR of 1.81 with (95% CI ¼ 1.02-3.21), so that VAS intensity was associated with neuropathic pain; no statistically significant relations were found between painDETECT scores !19 and age, gender, or presence of (HAD) anxiety and depression.
Discussion
Establishing the nature of the pain experienced by BMS patients is essential to providing a treatment that effectively relieves and manages orofacial pain. In this context, painDETECT (PD-Q) is a simple, patient-reported questionnaire designed to screen and identify neuropathic pain, often an element of BMS. It has been translated from German and validated in various languages including Spanish [12, 13] . In the present study, PD-Q identified seven of 33 BMS patients with scores of over 19, a similar finding to Heo et al. [8] . Neuropathic pain questionnaires are useful for standardizing characteristics associated with pain and for identifying possible BMS sufferers-probably their main clinical strength. These neuropathic pain detection tools are easy to use, and they generate information immediately.
A recent study by Braud et al. [9] used the validated neuropathic pain questionnaire Douleur Neuropathique 4 (DN4) to assess a sample of BMS patients; 13 of 22 patients (59%) obtained a DN4 score in favor of the neuropathic nature of BMS. Sevrain et al. [10] obtained a DN4 score !3 in 11 of 35 BMS patients (31%). While some neuropathic pain measurement instruments such as DN4 and the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) are combined with clinical exploration, PD-Q has the advantage of not requiring any additional examination.
In another study, PD-Q used to validate back pain found a sensitivity of 85% and specificity of 80% (applying a threshold of 19) [13] . When Heo et al. [8] compared neuropathic pain questionnaires (PD-Q and DN4) applied to BMS patients, the authors found less sensitivity and specificity than previously validated screening tools (PD-Q obtained a sensitivity of 16.7% with a specificity of 94.7%). Elias et al. [11] assessed the suitability of PD-Q to evaluate pain in patients with painful post-traumatic trigeminal nerve injuries; the sensitivity of detecting neuropathic trigeminal pain in this study was 34%.
Most questionnaires use the same pain descriptorsburning sensation, electric shock-like sensation, allodynia, pins and needles, prickling, numbness-as these are considered the central symptoms or keys features of neuropathic pain (6) . In the present study, pain DETECT identified statistically significant differences between the two groups for burning (P < 0.010), prickling (P ¼ 0.001), electric shock-like sensation (P ¼ 0.046), thermal sensation (P < 0.001), numbness (P ¼ 0.002)-useful information, although other authors claim that the questionnaire cannot replace clinical judgment [7, [12] [13] .
As Heo et al. observed [8] , the questionnaire suffers a lack of relevance in relation to orofacial pain; the question "Is light touching (clothing, a blanket) in this area painful?" does not adequately correspond to orofacial pain. Instead of this question, a further orofacial pain question might be introduced, such as "Is soft food or the light touch of the tongue in the mouth a cause of pain?" Freynhagen [13] also mentions the lack of pertinence of an image of the orofacial region included in the questionnaire, which the author argues should be on a larger scale in order to better describe the irradiation of orofacial pain, and so avoid confusion.
Several studies have shown that the neuropathic and psychological aspects of the disease coexist and should be actively investigated by clinicians for successful management of BMS [1, [18] [19] [20] [21] . The etiopathogenesis of BMS is controversial. Pain deriving from BMS is often accompanied by comorbidity, whereby in addition to pain patients are more prone to suffer behavioral disorders related to anxiety and depression. These can be understood in terms of feelings of vulnerability accompanying the chronic pain. Psychological disorders derive from combinations of determined symptoms so that physical and psychological characteristics are not mutually exclusive [1, [16] [17] [18] [19] .
The proportional involvement of peripheral and central neurogenic mechanisms of BMS pain has important implications for determining the main focus of treatment and for its effectiveness [1, 3, [22] [23] . Neuropathic pain is notoriously difficult to treat and tends to be refractory to the analgesics commonly used to treat nociceptive pain such as paracetamol and anti-inflammatory drugs. In this context, Gremeau-Richard et al. [23] performed peripheral lingual nerve block in BMS patients, obtaining relief of the pain in half the patients, which suggests that the mechanisms involved were predominantly peripheral. In another subgroup, anesthesia of the lingual nerve had no effect and even increased the intensity of the pain, indicating that central mechanisms predominated in the pain's physiopathology in this subgroup.
At the same time, topical clonazepam has been shown to be an effective treatment for BMS with peripheral nervous system alteration, but not central nervous system alteration [22] . Curiously, BMS patients with central nervous system alteration present more comorbid psychiatric problems such as depression and anxiety [23] . As we can see, the difficulty of treatment derives from the heterogeneity of neuropathic pain mechanisms and the frequent coexistence of psychological and emotional factors.
Sevrain et al. [10] were the first researchers to use neuropathic pain questionnaires to assess BMS and its psychological variations in 35 patients with primary BMS: 31% of them had a DN4 score in favor of neuropathic pain and 35.3% had a HADS overall score in favor of anxiety and depressive disorder. The study suffered several limitations such as the small sample size and the fact that a priori sample size calculation was not performed due to the uncertainty in prevalence of neuropathic pain in the sample. Although a questionnaire can provide important information, it is supplementary to a clinician's expert evaluation.
The present study suggests that almost a third of BMS patients present neuropathic pain, which is strongly associated with the intensity of pain measured using VAS. The use of simple routine diagnostic methods such as the PD-Q could help identify patients suffering neuropathic pain and make it possible to individualize the treatment and management of BMS.
